Reckitt Benckiser Group (LON:RB) Rating Reiterated by UBS Group

Reckitt Benckiser Group (LON:RB)‘s stock had its “neutral” rating reiterated by analysts at UBS Group in a research report issued on Thursday, Borsen Zeitung reports. They currently have a GBX 6,400 ($83.63) price objective on the stock. UBS Group’s price target would suggest a potential downside of 1.93% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Bryan, Garnier & Co assumed coverage on shares of Reckitt Benckiser Group in a research note on Friday, April 5th. They issued a “neutral” rating and a GBX 6,800 ($88.85) price target on the stock. Jefferies Financial Group reaffirmed an “underperform” rating and issued a GBX 5,400 ($70.56) price target (up previously from GBX 5,000 ($65.33)) on shares of Reckitt Benckiser Group in a research note on Friday, April 5th. Goldman Sachs Group set a GBX 6,820 ($89.12) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a research note on Thursday, May 2nd. Royal Bank of Canada set a GBX 5,300 ($69.25) target price on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a research report on Thursday, May 2nd. Finally, Shore Capital reissued an “under review” rating on shares of Reckitt Benckiser Group in a research report on Thursday, May 2nd. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 7,154.12 ($93.48).

RB stock traded down GBX 83 ($1.08) during trading on Thursday, hitting GBX 6,526 ($85.27). The company had a trading volume of 1,766,260 shares, compared to its average volume of 1,720,000. The company has a market capitalization of $46.26 billion and a PE ratio of 21.41. Reckitt Benckiser Group has a 52-week low of GBX 5,559 ($72.64) and a 52-week high of GBX 7,174 ($93.74). The company has a debt-to-equity ratio of 80.49, a current ratio of 0.65 and a quick ratio of 0.47.

In other news, insider Christopher Sinclair purchased 1,076 shares of the stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average cost of GBX 6,375 ($83.30) per share, for a total transaction of £68,595 ($89,631.52). Also, insider Andrew R. J. Bonfield purchased 146 shares of the stock in a transaction dated Tuesday, May 21st. The stock was purchased at an average price of GBX 6,290 ($82.19) per share, for a total transaction of £9,183.40 ($11,999.74).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

Featured Story: Trading Strategy

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.